Table 3.
Antibiotic and anti-viral treatment in diabetic patients with SARS symptoms, hospitalized, COVID positive PCR during 4 months
| Diabetic Patients With SARS Symptoms | Hospitalized (N = 21,247) | COVID PCR Positive (N = 8235) |
|---|---|---|
| Antibiotic treatment | 7267(34.20) | 2845(34.55) |
| Anti-viral treatment | 5133 (24.16) | 2633(31.97) |
| Types of antibiotics | ||
| Cephalosporin | 3892(18.32) | 1467(17.81) |
| Macrolide | 2894(13.62) | 1276(15.49) |
| Broad-Spectrum Antibiotic | 2228(10.49) | 854(10.37) |
| Fluoroquinolone | 701(3.30) | 341 (3.97) |
| Clindamycin | 209(0.98) | 53 (0.64) |
| Metronidazole | 44(0.21) | 2(0.02) |
| Aminoglycoside | 27(0.13) | 6(0.07) |
| Other Drug | ||
| Hydroxychloroquine | 5916(27.84) | 2689(32.65) |
| Antiviral Treatment | ||
| Kaletra | 3312(15.59) | 1674(20.33) |
| Oseltamivir | 2593(12.20) | 1455(17.67) |
| Ribavirin | 235(1.11) | 117(1.42) |
| Atazanavir | 19(0.09) | 12(0.15) |
| Interferon | 5(0.02) | 4(0.05) |
| Recommended treatment for patients with pneumoniaa | 1762 (8.29) | 755(9.17) |
aTavanex/Levofloxacin or TazocinPiperacillin/Tazobactam or Ceftazidime or Vancomycin or Amoxicillin/ CoAmoxiclav or Clarithromycin/ Erythromycin